


CLAIMS

1. Compound corresponding to formula (I):



5 in which:

- W represents a nitrogen atom or a group CH;
- Y represents a group C₂-C₃-alkynylene, a 1,4-phenylene optionally substituted with R₇ which represents one or more halogen atom(s);
- Z represents a bond or a group CR₁R₂;
- 10 - R₁ and R₂, independently of each other, represent a group chosen from a hydrogen atom, a group C₁-C₆-alkyl, a trifluoromethyl group, a group (CH₂)_nOR₆, C₃-C₇-cycloalkyl, an heteroaryl or an aryl optionally substituted with one or more halogen atom(s);
- R₁ and R₂ can form together, with the carbon atom which bear them, a C₃-C₇-cycloalkyl;
- 15 - R₃ represents a hydrogen atom;
- R₄ represents a group chosen from a group C₁-C₆-alkyl, a group (CH₂)_nOR₆, C₃-C₇-cycloalkyl or C₁-C₆-alkyl optionally substituted by a C₃-C₇-cycloalkyl;
- R₅ represents a group chosen from a hydrogen atom or a group C₁-C₆-alkyl;
- 20 - R₆ represents a group chosen from a hydrogen atom or a group C₁-C₆-alkyl;
- n is equal to 1, 2 or 3;

in the form of the base or of an acid-addition salt.

25 2. Compound of formula (I) according to Claim 1, characterized in that W represents a nitrogen atom or a group CH, in the form of the base or of an acid-addition salt.

3. Compound of formula (I) according to Claim 1 or 2, characterized in that W represents a nitrogen atom, in the form of the base or of an acid-addition salt.

4. Compound of formula (I) according to any one of Claims 1 to 3, characterized in that Y represents a group C₂-C₃-alkynylene,, more particularly ethynylene, in the form of the base or of an acid-addition salt.

5. Compound of formula (I) according to any one of Claims 1 to 4, characterized in that:

- Z represents a bond, a group CR₁R₂;
 - R₁ represents a group chosen from a hydrogen atom, a group C₁-C₆-alkyl, a group (CH₂)_nOR₆, C₃-C₇-cycloalkyl, an aryl or a 5- or 6-membered-heteroaryl;
 - R₂ represents a group chosen from a hydrogen atom, a group C₁-C₆-alkyl or a trifluoromethyl;
 - R₆ represents a group chosen from a hydrogen atom or a group C₁-C₆-alkyl;
 - n is equal to 1, 2 or 3;
- in the form of the base or of an acid-addition salt.

6. Compound of formula (I) according to any one of Claims 1 to 5, characterized in that:

- Z represents a group CR₁R₂;
 - R₁ represents a group chosen from a hydrogen atom, a group C₁-C₆-alkyl, a group (CH₂)_nOR₆, C₃-C₇-cycloalkyl, an aryl or a 5- or 6-membered-heteroaryl;
 - R₂ represents a group chosen from a hydrogen atom, a group C₁-C₆-alkyl or a trifluoromethyl;
 - R₆ represents a group chosen from a hydrogen atom or a group C₁-C₆-alkyl;
- and
- n is equal to 1, 2 or 3;
- in the form of the base or of an acid-addition salt.

7. Compound of formula (I) according to any one of Claims 1 to 6, characterized in that R₄ represents a group chosen from a group C₁-C₆-alkyl, a group (CH₂)_nOR₆, C₃-C₇-cycloalkyl or C₁-C₆-alkyl optionally substituted by a C₃-C₇-cycloalkyl, in the form of the base or of an acid-addition salt.

8. Compound of formula (I) according to any one of Claims 1 to 7, characterized in that R₄ represents a group C₁-C₆-alkyl, more particularly an ethyl, in the form of the base or of an acid-addition salt.

9. Compound of formula (I) according to any one of Claims 1 to 8, characterized in that R_5 represents a group chosen from a hydrogen atom or a group C_1 - C_6 -alkyl, in the form of the base or of an acid-addition salt.

10. Compound of formula (I) according to any one of Claims 1 to 9, characterized in that R_5 represents a hydrogen atom, in the form of the base or of an acid-addition salt.

11. Compound of formula (I) according to any one of Claims 1 to 10, characterized in that:

- W represents a nitrogen atom or a group CH;
- 10 - Y represents a group C_2 - C_3 -alkyne or a 1,4-phenylene optionally substituted with R_7 which represents a halogen atom;
- Z represents a bond, a group CR_1R_2 ;
- R_1 represents a group chosen from a hydrogen atom, a group C_1 - C_6 -alkyl, a group $(CH_2)_nOR_6$, C_3 - C_7 -cycloalkyl, an aryl or a 5- or 6-membered-heteroaryl
- 15 optionally substituted with a halogen atom;
- R_2 represents a group chosen from a hydrogen atom, a group C_1 - C_6 -alkyl or a trifluoromethyl;
- R_3 represents a hydrogen atom ;
- R_4 represents a group chosen from a group C_1 - C_6 -alkyl, a group $(CH_2)_nOR_6$,
- 20 C_3 - C_7 -cycloalkyl or C_1 - C_6 -alkyl optionally substituted by a C_3 - C_7 -cycloalkyl;
- R_5 represents a group chosen from a hydrogen atom or a group C_1 - C_6 -alkyl;
- R_6 represents a group chosen from a hydrogen atom or a group C_1 - C_6 -alkyl;
- n is equal to 1, 2 or 3;

in the form of the base or of an acid-addition salt.

25 12. Compound of formula (I) according to any one of Claims 1 to 11, characterized in that R_1 and R_2 form together, with the carbon atom which bear them, a C_3 - C_7 -cycloalkyl, in the form of the base or of an acid-addition salt.

13. Compound of formula (I) according to Claim 1, chosen from:


30 2-Amino-1-ethyl-7-((3R)-3-hydroxy-4-methoxy-3-methyl-but-1-ynyl)-3-(1H-imidazol-2-yl)-1H-[1,8]naphthyridin-4-one

2-Amino-1-propyl-7-((3R)-3-hydroxy-4-methoxy-3-methyl-but-1-ynyl)-3-(1H-imidazol-2-yl)-1H-[1,8]naphthyridin-4-one


- 2-Amino-7-(3,4-dihydroxy-3-methyl-but-1-ynyl)-1-ethyl-3-(1H-imidazol-2-yl)-1H-[1,8]naphthyridin-4-one
- 2-Amino-1-ethyl-7-(3-hydroxy-3-pyridin-2-yl-but-1-ynyl)-3-(1H-imidazol-2-yl)-1H-[1,8]naphthyridin-4-one
- 5 2-Amino-1-ethyl-7-[(3R)-3-hydroxy-4-methoxy-3-methyl-but-1-ynyl]-3-(4-methyl-1H-imidazol-2-yl)-1H-[1,8]naphthyridin-4-one
- 2-Amino-1-(cyclopropylmethyl)-7-(3-hydroxy-pent-1-ynyl)-3-(1H-imidazol-2-yl)-1H-[1,8]naphthyridin-4-one
- 10 2-Amino-1-ethyl-7-[(3R)-3-hydroxy-4-methoxy-3-methyl-but-1-ynyl]-3-(1H-imidazol-2-yl)-1H-quinolin-4-one
- 2-Amino-7-(3-chloro-4-hydroxy-phenyl)-1-ethyl-3-(1H-imidazol-2-yl)-1H-[1,8]naphthyridin-4-one
- 2-Amino-1-ethyl-7-[3-(2-fluorophenyl)-3-hydroxy-but-1-ynyl]-3-(1H-imidazol-2-yl)-1H-[1,8]naphthyridin-4-one
- 15 2-Amino-1-cyclopentyl-7-(3-hydroxy-pent-1-ynyl)-3-(1H-imidazol-2-yl)-1H-[1,8]naphthyridin-4-one
- 2-Amino-7-(3-hydroxy-pent-1-ynyl)-3-(1H-imidazol-2-yl)-1-(3-methoxypropyl)-1H-[1,8]naphthyridin-4-one
- 2-Amino-7-(3-hydroxy-pent-1-ynyl)-3-(1H-imidazol-2-yl)-1-(2-methoxyethyl)-1H-[1,8]naphthyridin-4-one
- 20 2-Amino-1-ethyl-7-[(1-hydroxycyclobutyl)ethynyl]-3-(1H-imidazol-2-yl)-1H-[1,8]naphthyridin-4-one
- 2-Amino-1-ethyl-7-[(1-hydroxycyclopentyl)ethynyl]-3-(1H-imidazol-2-yl)-1H-[1,8]naphthyridin-4-one
- 25 2-Amino-1-ethyl-7-(3-hydroxy-3-methyl-but-1-ynyl)-3-(1H-imidazol-2-yl)-1H-[1,8]naphthyridin-4-one
- 2-Amino-1-ethyl-7-(3-hydroxy-3-methyl-pent-1-ynyl)-3-(1H-imidazol-2-yl)-1H-[1,8]naphthyridin-4-one
- 2-Amino-1-ethyl-7-(3-hydroxy-3-phenyl-but-1-ynyl)-3-(1H-imidazol-2-yl)-1H-[1,8]naphthyridin-4-one
- 30 2-Amino-1-ethyl-7-[3-(3-fluorophenyl)-3-hydroxy-but-1-ynyl]-3-(1H-imidazol-2-yl)-1H-[1,8]naphthyridin-4-one

- 2-Amino-1-ethyl-3-(1H-imidazol-2-yl)-7-(4,4,4-trifluoro-3-hydroxy-3-phenyl-but-1-ynyl)-1H-[1,8]naphthyridin-4-one
- 2-Amino-7-(3-cyclopropyl-3-hydroxy-but-1-ynyl)-1-ethyl-3-(1H-imidazol-2-yl)-1H-[1,8]naphthyridin-4-one
- 5 2-Amino-1-ethyl-7-[3-hydroxy-3-(thiophen-2-yl)but-1-ynyl]-3-(1H-imidazol-2-yl)-1H-[1,8]naphthyridin-4-one
- 2-Amino-1-ethyl-7-(3-hydroxy-but-1-ynyl)-3-(1H-imidazol-2-yl)-1H-[1,8]naphthyridin-4-one
- 10 2-Amino-1-ethyl-7-(3-hydroxy-pent-1-ynyl)-3-(1H-imidazol-2-yl)-1H-[1,8]naphthyridin-4-one
- 2-Amino-1-ethyl-7-(3-hydroxy-hex-1-ynyl)-3-(1H-imidazol-2-yl)-1H-[1,8]naphthyridin-4-one
- 2-Amino-1-ethyl-7-(3-hydroxy-4-methyl-pent-1-ynyl)-3-(1H-imidazol-2-yl)-1H-[1,8]naphthyridin-4-one
- 15 2-Amino-1-ethyl-7-(3-hydroxy-3-phenyl-prop-1-ynyl)-3-(1H-imidazol-2-yl)-1H-[1,8]naphthyridin-4-one
- 2-Amino-7-((3R)-3,4-dihydroxy-3-methyl-but-1-ynyl)-1-ethyl-3-(1H-imidazol-2-yl)-1,8-naphthyridin-4(1H)-one
- 2-Amino-7-((3S)-3,4-dihydroxy-3-methyl-but-1-ynyl)-1-ethyl-3-(1H-imidazol-2-yl)-1,8-naphthyridin-4(1H)-one
- 20 2-Amino-1-ethyl-7-((3S)-3-hydroxy-4-methoxy-3-methyl-but-1-ynyl)-3-(1H-imidazol-2-yl)-1,8-naphthyridin-4(1H)-one.

14. Process for preparing a compound of formula (I) according to any one of
25 Claims 1 to 13, characterized in that a compound of formula (VII):




in which X is a chlorine or a bromine and R₄ and R₅ are as defined in the general formula (I) according to any one of Claims 1 to 14, is reacted with a compound of general formula (XVa):



in which R₁, R₂ and R₃ are as defined in the general formula (I) according to any one of Claims 1 to 13,

or is reacted with a compound of general formula (XVb):



in which R₃ and R₇ are as defined in the general formula (I) according to any one of Claims 1 to 13,

a conventional stage of deprotection being carried out before or after the reaction of the compound of formula (VII) with the compound of general formula (XVa) or the compound of general formula (XVb).

15. Medicament comprising a compound of formula (I) according to any one of Claims 1 to 13, or a pharmaceutically acceptable salt, or an enantiomer or a diastereoisomer, or a mixture thereof.

16. A pharmaceutical composition comprising a compound according to any one of Claims 1 to 13, or a pharmaceutically acceptable salt thereof, or an enantiomer or a diastereoisomer, or a mixture thereof, and also at least one pharmaceutically acceptable excipient.

17. The combination of a compound of formula (I) according to any one of Claims 1 to 13 with at least one therapeutic agent selected from:

- alkylating agents,
- intercalating agents,

- antimicrotubule agents,
- antimitotics,
- antimetabolites,
- antiproliferative agents,
- 5 - antibiotics,
- immunomodulatory agents,
- anti-inflammatories,
- kinase inhibitors,
- anti-angiogenic agents,
- 10 - antivascular agents,
- oestrogenic and androgenic hormones.

18. Compound of formula (I) according to any one of Claims 1 to 13 for use in the preparation of a medicament for preventing and/or treating diseases in which VEGFR-3 is involved.

15 19. Compound of formula (I) according to any one of Claims 1 to 13 for use in the preparation of a medicament for preventing and/or treating cancer and metastases.

20 20. Compound of formula (I) according to any one of Claims 1 to 13 for use in the preparation of a medicament for preventing and/or treating glioblastomas, multiple myelomas, myelodysplastic syndromes, Kaposi's sarcomas, cutaneous angiosarcomas, solid tumours, lymphomas, melanomas, breast cancers, colorectal cancers, lung cancers, including non-small-cell cancers, pancreatic cancers, prostate cancers, kidney cancers, head and neck cancers, liver cancer, ovarian cancers, cancers of the respiratory tract and chest, or other tumours expressing VEGFR-3 or involving a process of angiogenesis or of lymphangiogenesis.

25 21. Compound of formula (I) according to any one of Claims 1 to 13 for use in the preparation of a medicament for preventing and/or treating non-oncological proliferative disease or pathological angiogenesis linked to VEGFR-3.

30 22. Compound of formula (I) according to any one of Claims 1 to 13 for use in the preparation of a medicament for preventing and/or treating diseases selected from the group consisting of arthrosis, restenosis, psoriasis, hemangiomas, lymphangiomas, glaucomas, glomerulonephritis, diabetic nephropathies, nephrosclerosis, thrombotic


microangiopathic syndromes, liver cirrhosis, atherosclerosis, organ transplant rejection, or eye diseases involving a process of angiogenesis or of lymphangiogenesis.

23. Compound of formula (I) according to any one of Claims 1 to 13 for use in the preparation of a medicament for preventing and/or treating chronic or non-chronic
5 inflammation, infection with microorganisms and of autoimmune diseases, such as rheumatoid arthritis.

24. Compound of formula (I) according to any one of Claims 1 to 13 for use in the preparation of a medicament for preventing and/or treating rare diseases such as lymphagiocleiomyomatosis or Gorham's Disease

CLAIMS

1. Use of a compound corresponding to formula (I):



5 in which:

- W represents a nitrogen atom or a group CH;
- Y represents a group C₂-C₃-alkynylene, a 1,4-phenylene optionally substituted with R₇ which represents one or more halogen atom(s);

- Z represents a bond or a group CR₁R₂;

10 - R₁ and R₂, independently of each other, represent a group chosen from a hydrogen atom, a group C₁-C₆-alkyl, a trifluoromethyl group, a group (CH₂)_nOR₆, C₃-C₇-cycloalkyl, an heteroaryl or an aryl optionally substituted with one or more halogen atom(s);

- R₁ and R₂ can form together, with the carbon atom which bear them, a C₃-C₇-cycloalkyl;

15 - R₃ represents a hydrogen atom;

- R₄ represents a group chosen from a group C₁-C₆-alkyl, a group (CH₂)_nOR₆, C₃-C₇-cycloalkyl or C₁-C₆-alkyl optionally substituted by a C₃-C₇-cycloalkyl;

- R₅ represents a group chosen from a hydrogen atom or a group C₁-C₆-alkyl;

- R₆ represents a group chosen from a hydrogen atom or a group C₁-C₆-alkyl;

20 - n is equal to 1, 2 or 3;

in the form of the base or of an acid-addition salt; or

a pharmaceutically acceptable salt thereof; or

an enantiomer or a diastereoisomer; or

a mixture thereof;

25 in the manufacture of a medicament for preventing and/or treating diseases in which VEGFR-3 is involved.

2. The use according to claim 1, wherein the disease is cancer and metastases, more particularly glioblastomas, multiple myelomas, myelodysplastic syndromes, Kaposi's sarcomas, cutaneous angiosarcomas, solid tumours, lymphomas, melanomas, breast cancers, colorectal cancers, lung cancers, including non-small-cell cancers, pancreatic cancers, prostate
 5 cancers, kidney cancers, head and neck cancers, liver cancer, ovarian cancers, cancers of the respiratory tract and chest, or other tumours expressing VEGFR-3 or involving a process of angiogenesis or of lymphangiogenesis.

3. The use according to claim 1, wherein the disease is non-oncological proliferative
 10 disease or pathological angiogenesis linked to VEGFR-3.

4. The use according to claim 1, wherein the disease is selected from the group consisting of arthrosis, restenosis, psoriasis, hemangiomas, lymphangiomas, glaucomas, glomerulonephritis, diabetic nephropathies, nephrosclerosis, thrombotic microangiopathic
 15 syndromes, liver cirrhosis, atherosclerosis, organ transplant rejection, or eye diseases involving a process of angiogenesis or of lymphangiogenesis or chronic or non-chronic inflammation, infection with microorganisms and of autoimmune diseases, such as rheumatoid arthritis or rare diseases such as lymphagiroleiomyomatosis or Gorham's Disease.

20 5. The use according to any of claims 1-4, wherein W represents a nitrogen atom or a group CH, more particularly a nitrogen atom.

6. The use according to any of claims 1-5, wherein Y represents a group C₂-C₃-alkynylene, more particularly ethynylene.

25

7. The use according to any of claims 1-6, wherein:

- Z represents a bond, a group CR₁R₂; more particularly a group CR₁R₂;

- R₁ represents a group chosen from a hydrogen atom, a group C₁-C₆-alkyl, a group (CH₂)_nOR₆, C₃-C₇-cycloalkyl, an aryl or a 5- or 6-membered-heteroaryl;

30 - R₂ represents a group chosen from a hydrogen atom, a group C₁-C₆-alkyl or a trifluoromethyl;

- R₆ represents a group chosen from a hydrogen atom or a group C₁-C₆-alkyl;

- n is equal to 1, 2 or 3.

8. The use according to any of claims 1-7, wherein R_4 represents a group chosen from a group C_1 - C_6 -alkyl, a group $(CH_2)_nOR_6$, C_3 - C_7 -cycloalkyl or C_1 - C_6 -alkyl optionally substituted by a C_3 - C_7 -cycloalkyl, preferably R_4 represents a group C_1 - C_6 -alkyl, and more particularly an ethyl.

5

9. The use according to any of claims 1-8, wherein R_5 represents a group chosen from a hydrogen atom or a group C_1 - C_6 -alkyl, more particularly a hydrogen atom.

10. The use according to any of claims 1-9, wherein:

10

- W represents a nitrogen atom or a group CH ;
- Y represents a group C_2 - C_3 -alkyne or a 1,4-phenylene optionally substituted with R_7 which represents a halogen atom;

- Z represents a bond, a group CR_1R_2 ;

15

- R_1 represents a group chosen from a hydrogen atom, a group C_1 - C_6 -alkyl, a group $(CH_2)_nOR_6$, C_3 - C_7 -cycloalkyl, an aryl or a 5- or 6-membered-heteroaryl optionally substituted with a halogen atom;

- R_2 represents a group chosen from a hydrogen atom, a group C_1 - C_6 -alkyl or a trifluoromethyl;

- R_3 represents a hydrogen atom ;

20

- R_4 represents a group chosen from a group C_1 - C_6 -alkyl, a group $(CH_2)_nOR_6$, C_3 - C_7 -cycloalkyl or C_1 - C_6 -alkyl optionally substituted by a C_3 - C_7 -cycloalkyl;

- R_5 represents a group chosen from a hydrogen atom or a group C_1 - C_6 -alkyl;

- R_6 represents a group chosen from a hydrogen atom or a group C_1 - C_6 -alkyl;

- n is equal to 1, 2 or 3.

25

11. The use according to any of claims 1-10, wherein R_1 and R_2 form together, with the carbon atom which bear them, a C_3 - C_7 -cycloalkyl.

12. The use according to any of claims 1-4, wherein the compound is chosen from:

30

2-Amino-1-ethyl-7-((3R)-3-hydroxy-4-methoxy-3-methyl-but-1-ynyl)-3-(1H-imidazol-2-yl)-1H-[1,8]naphthyridin-4-one

2-Amino-1-propyl-7-((3R)-3-hydroxy-4-methoxy-3-methyl-but-1-ynyl)-3-(1H-imidazol-2-yl)-1H-[1,8]naphthyridin-4-one

2-Amino-7-(3,4-dihydroxy-3-methyl-but-1-ynyl)-1-ethyl-3-(1H-imidazol-2-yl)-1H-[1,8]naphthyridin-4-one

2-Amino-1-ethyl-7-(3-hydroxy-3-pyridin-2-yl-but-1-ynyl)-3-(1H-imidazol-2-yl)-1H-[1,8]naphthyridin-4-one

5 2-Amino-1-ethyl-7-[(3R)-3-hydroxy-4-methoxy-3-methyl-but-1-ynyl]-3-(4-methyl-1H-imidazol-2-yl)-1H-[1,8]naphthyridin-4-one

2-Amino-1-(cyclopropylmethyl)-7-(3-hydroxy-pent-1-ynyl)-3-(1H-imidazol-2-yl)-1H-[1,8]naphthyridin-4-one

10 2-Amino-1-ethyl-7-[(3R)-3-hydroxy-4-methoxy-3-methyl-but-1-ynyl]-3-(1H-imidazol-2-yl)-1H-quinolin-4-one

2-Amino-7-(3-chloro-4-hydroxy-phenyl)-1-ethyl-3-(1H-imidazol-2-yl)-1H-[1,8]naphthyridin-4-one

2-Amino-1-ethyl-7-[3-(2-fluorophenyl)-3-hydroxy-but-1-ynyl]-3-(1H-imidazol-2-yl)-1H-[1,8]naphthyridin-4-one

15 2-Amino-1-cyclopentyl-7-(3-hydroxy-pent-1-ynyl)-3-(1H-imidazol-2-yl)-1H-[1,8]naphthyridin-4-one

2-Amino-7-(3-hydroxy-pent-1-ynyl)-3-(1H-imidazol-2-yl)-1-(3-methoxypropyl)-1H-[1,8]naphthyridin-4-one

20 2-Amino-7-(3-hydroxy-pent-1-ynyl)-3-(1H-imidazol-2-yl)-1-(2-methoxyethyl)-1H-[1,8]naphthyridin-4-one

2-Amino-1-ethyl-7-[(1-hydroxycyclobutyl)ethynyl]-3-(1H-imidazol-2-yl)-1H-[1,8]naphthyridin-4-one

2-Amino-1-ethyl-7-[(1-hydroxycyclopentyl)ethynyl]-3-(1H-imidazol-2-yl)-1H-[1,8]naphthyridin-4-one

25 2-Amino-1-ethyl-7-(3-hydroxy-3-methyl-but-1-ynyl)-3-(1H-imidazol-2-yl)-1H-[1,8]naphthyridin-4-one

2-Amino-1-ethyl-7-(3-hydroxy-3-methyl-pent-1-ynyl)-3-(1H-imidazol-2-yl)-1H-[1,8]naphthyridin-4-one

30 2-Amino-1-ethyl-7-(3-hydroxy-3-phenyl-but-1-ynyl)-3-(1H-imidazol-2-yl)-1H-[1,8]naphthyridin-4-one

2-Amino-1-ethyl-7-[3-(3-fluorophenyl)-3-hydroxy-but-1-ynyl]-3-(1H-imidazol-2-yl)-1H-[1,8]naphthyridin-4-one

2-Amino-1-ethyl-3-(1H-imidazol-2-yl)-7-(4,4,4-trifluoro-3-hydroxy-3-phenyl-but-1-ynyl)-1H-[1,8]naphthyridin-4-one

2-Amino-7-(3-cyclopropyl-3-hydroxy-but-1-ynyl)-1-ethyl-3-(1H-imidazol-2-yl)-1H-[1,8]naphthyridin-4-one

2-Amino-1-ethyl-7-[3-hydroxy-3-(thiophen-2-yl)but-1-ynyl]-3-(1H-imidazol-2-yl)-1H-[1,8]naphthyridin-4-one

5 2-Amino-1-ethyl-7-(3-hydroxy-but-1-ynyl)-3-(1H-imidazol-2-yl)-1H-[1,8]naphthyridin-4-one

2-Amino-1-ethyl-7-(3-hydroxy-pent-1-ynyl)-3-(1H-imidazol-2-yl)-1H-[1,8]naphthyridin-4-one

10 2-Amino-1-ethyl-7-(3-hydroxy-hex-1-ynyl)-3-(1H-imidazol-2-yl)-1H-[1,8]naphthyridin-4-one

2-Amino-1-ethyl-7-(3-hydroxy-4-methyl-pent-1-ynyl)-3-(1H-imidazol-2-yl)-1H-[1,8]naphthyridin-4-one

2-Amino-1-ethyl-7-(3-hydroxy-3-phenyl-prop-1-ynyl)-3-(1H-imidazol-2-yl)-1H-[1,8]naphthyridin-4-one

15 2-Amino-7-((3R)3,4-dihydroxy-3-methyl-but-1-ynyl)-1-ethyl-3-(1H-imidazol-2-yl)-1,8-naphthyridin-4(1H)-one

2-Amino-7-((3S)3,4-dihydroxy-3-methyl-but-1-ynyl)-1-ethyl-3-(1H-imidazol-2-yl)-1,8-naphthyridin-4(1H)-one

20 2-Amino-1-ethyl-7-((3S)-3-hydroxy-4-methoxy-3-methyl-but-1-ynyl)-3-(1H-imidazol-2-yl)-1,8-naphthyridin-4(1H)-one.

13. The use according to any of claims 1-12, wherein the medicament further comprises at least one pharmaceutically acceptable excipient.

25 14. The use according to any of claims 1-12, wherein the medicament further comprises at least one therapeutic agent selected from:

- alkylating agents,
- intercalating agents,
- antimicrotubule agents,
- 30 - antimitotics,
- antimetabolites,
- antiproliferative agents,
- antibiotics,
- immunomodulatory agents,

- anti-inflammatories,
- kinase inhibitors,
- anti-angiogenic agents,
- antivascular agents,
- oestrogenic and androgenic hormones.